Researchers in Australia have developed a blood test for Alzheimer's disease that delivers results in 18 minutes [1].
This development could fundamentally change how the disease is diagnosed by removing the need for invasive and expensive imaging. Faster detection allows patients to access treatment earlier and reduces the likelihood of misdiagnosis.
The project was led by Professor Matthew Kiernan, the CEO of Neuroscience Research Australia [1]. The team aims to provide a diagnostic method that is faster, cheaper, and less invasive than current standards of care.
Currently, many patients rely on PET brain scans to confirm an Alzheimer's diagnosis. These scans are costly, typically ranging from $5,000 to $7,000 [2]. The new blood test is designed to replace these scans by offering a more accessible alternative.
Beyond the immediate clinical benefit, the researchers intend for the test to eventually be covered by Medicare [1]. This move would further lower the financial barrier for patients seeking a definitive diagnosis.
By streamlining the process, the test reduces the time between the onset of symptoms and the start of medical intervention. The shift toward blood-based biomarkers represents a broader trend in neurology to move away from expensive imaging toward rapid chemical analysis.
“The new blood test for Alzheimer's disease delivers results in 18 minutes.”
The transition from high-cost imaging to rapid blood tests could democratize Alzheimer's diagnostics. By reducing the cost and time associated with PET scans, healthcare systems can screen larger populations earlier, potentially improving the efficacy of treatments that are most effective in the early stages of the disease.
